Import Bortezomib — Buy in Bulk from Supplier in China

Bortezomib is a proteasome inhibitor employed in the treatment of multiple myeloma and certain lymphomas. The compound is identified by the CAS number 205393-22-2, which provides a precise chemical reference for procurement. It is supplied in injectable formulations suitable for hospital administration. The listing notes that the product is manufactured under ISO and FDA‑aligned quality controls.

The manufacturing process follows standard pharmaceutical practices for sterile injectable drugs, including aseptic filling and container‑closure integrity testing. Typical industry specifications for Bortezomib include a purity of at least 99 % and a storage temperature of 2‑8 °C to maintain stability. Suppliers usually provide the drug in single‑use vials of 1 mg or 3 mg, wrapped in protective secondary packaging.

Hospital pharmacies, oncology clinics and pharmaceutical distributors are the primary buyers of this oncology agent. Trade terms referenced include FOB or CIF shipping and payment options such as L/C and T/T, but exact conditions must be negotiated with the supplier. Prospective importers should confirm the minimum order quantity, required certifications and any import licences before committing to purchase.

Shengdapharm is situated at 910 Huashenghui Building, Xixiang, Shenzhen, Baoan District, China. The supplier carries an imported tier designation and a harbor trust tier, indicating a basic level of verification. Its response statistics show a 0 % response rate with no recorded average response time, suggesting limited recent engagement.

The company’s product portfolio includes Bortezomib and potentially other oncology agents, produced under ISO and FDA‑aligned quality systems. No specific export licences or additional certifications are listed, so buyers should request the relevant certificates of analysis and GMP compliance documents. Shengdapharm presents itself as a source for pharmaceutical ingredients for hospitals and distributors.